The current stock price of EPIX is 0.2012 USD. In the past month the price decreased by -1.85%. In the past year, price decreased by -96.77%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.2 | 404.22B | ||
| AMGN | AMGEN INC | 15.55 | 183.17B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.35 | 116.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.06 | 75.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.43 | 61.48B | ||
| INSM | INSMED INC | N/A | 43.73B | ||
| NTRA | NATERA INC | N/A | 33.41B | ||
| BIIB | BIOGEN INC | 10.87 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.85B | ||
| INCY | INCYTE CORP | 15.65 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with a focus on advanced prostate cancer. The company is headquartered in Vancouver, British Columbia and currently employs 35 full-time employees. The company went IPO on 2021-02-22. The firm is undergoing a comprehensive review process to review its strategic options to maximize shareholder value.
ESSA Pharma Inc
999 West Broadway, Suite 720
Vancouver BRITISH COLUMBIA V5Z 1K5 CA
CEO: David Parkinson
Employees: 35
Phone: 17783310962
ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with a focus on advanced prostate cancer. The company is headquartered in Vancouver, British Columbia and currently employs 35 full-time employees. The company went IPO on 2021-02-22. The firm is undergoing a comprehensive review process to review its strategic options to maximize shareholder value.
The current stock price of EPIX is 0.2012 USD. The price decreased by -1.85% in the last trading session.
EPIX does not pay a dividend.
EPIX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
EPIX stock is listed on the Nasdaq exchange.
ESSA Pharma Inc (EPIX) will report earnings on 2025-12-15, after the market close.
ChartMill assigns a fundamental rating of 3 / 10 to EPIX. While EPIX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months EPIX reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -6.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.73% | ||
| ROE | -23.07% | ||
| Debt/Equity | 0 |
7 analysts have analysed EPIX and the average price target is 1.73 USD. This implies a price increase of 761.83% is expected in the next year compared to the current price of 0.2012.